One in Six US Drugs Will Soon Be Made in Israel
Image by Getty Images
JERUSALEM (JTA) – Israel-based Teva Pharmaceutical Industries has completed its $40 billion purchase of the generic medicine division of Allergan, its chief competitor.
As part of the deal completed on Tuesday, Allergan received $33.4 billion in cash and 100.3 million shares of Teva stock.
Allergan’s Anda Inc is the 4th-largest distributor of generic pharmaceuticals in the U.S. Anda distributes generic, brand, specialty and over-the-counter pharmaceutical products from more than 300 manufacturers to pharmacies, nursing homes, hospitals, clinics and physician offices across the United States.
Teva is the world’s largest manufacturer of generic drugs. Anda will continue to operate as a standalone division, Teva said in a statement issued Tuesday.
Teva CEO Erez Vigodman said Tuesday in an interview with the French news agency AFP that the acquisition is part of a wider plan to become one of the “most competitive, fully integrated companies in the industry.”
He told AFP that, in the wake of the deal, “one in six prescriptions in the U.S. (will be) Teva, one in six in the U.K., one in eight in Germany.” He denied that the acquisition would lead to higher generic drug prices.
The sale is subject to anti-trust clearance. Teva reportedly will have to sell off 79 of its pharmaceutical products in order to come into compliance.
A message from our CEO & publisher Rachel Fishman Feddersen
I hope you appreciated this article. Before you move on, I wanted to ask you to support the Forward’s award-winning journalism during our High Holiday Monthly Donor Drive.
If you’ve turned to the Forward in the past 12 months to better understand the world around you, we hope you will support us with a gift now. Your support has a direct impact, giving us the resources we need to report from Israel and around the U.S., across college campuses, and wherever there is news of importance to American Jews.
Make a monthly or one-time gift and support Jewish journalism throughout 5785. The first six months of your monthly gift will be matched for twice the investment in independent Jewish journalism.
— Rachel Fishman Feddersen, Publisher and CEO
